FDA approves Zohydro without abuse-deterrent formulation

10/30/2013 | MedPage Today (free registration)

The FDA's approval of the opoid painkiller Zohydro last week came without a requirement that the drug have biochemical mechanisms to control abuse, setting it apart from other drugs, such as OxyContin and Opana, that have abuse-deterrent formulations. Zogenix, the pharmaceutical company that developed Zohydro, said it plans to offer an abuse-deterrent form of the drug and an FDA representative said the agency makes decisions on abuse-deterrent requirements on a case-by-case basis.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI